Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Statement

2 Nov 2017 07:00

RNS Number : 3058V
Elektron Technology PLC
02 November 2017
 

Elektron Technology plc

("Elektron", the "Group" or the "Company")

 

Trading Update

 

Elektron Technology plc (AIM: EKT), the global technology group, is pleased to provide an update on trading for the third quarter ended 31 October 2017.

Sales

Group trading was strong in Q3 with sales increasing 34% compared to the same period last year to £8.6m (2017: £6.4m). Year to date sales have increased by 15% to £22.9m (2017: £19.9m).

Bulgin achieved record quarterly sales of £7.8m in Q3, 37% higher than the same period last year (2017: £5.7m) following successful manufacturing scale-up to convert the unprecedented order demand in H1 into sales. The board expects that Bulgin sales will revert to more normal levels through Q4.

 

Sales £m

Unaudited

Unaudited

Q3 2018

Q3 2017

YTD 2018

YTD 2017

Bulgin

7.8

5.7

20.3

17.4

IMC (Queensgate and Elektron Eye Technology)

0.7

0.7

2.3

2.3

Checkit

0.1

0.3

0.2

 

Total

 

8.6

 

6.4

 

22.9

 

19.9

 

Orders

Group order intake remains well ahead of prior year, with all business segments demonstrating growth.

Bulgin and IMC orders are both 20% above prior year levels year to date.

Checkit has continued to build recurring revenue streams and total contracted annual recurring revenue (including forthcoming contracted installations) now stands at £0.7m, compared with £0.3m at the same time last year (+133%).

Cash

Group net cash was approximately £3.0m at 31 October 2017 (31 July 2017: £2.0m; 31 January 2017: £1.0m) following the initial proceeds from the Sheen Instruments disposal of £1.1m in October. The net cash position has also been impacted by investment in working capital of approximately £0.4m as a result of the strong trading performance in this quarter.

John Wilson, Chief Executive Officer of Elektron, said:

"Q3 trading has been strong. The Board now expects full year performance to be ahead of its previous expectations."

Enquiries:

 

Elektron Technology plc 

www.elektron-technology.com

 

+44 (0) 1223 371 000

John Wilson - Chief Executive Officer

 

Andy Weatherstone - Chief Financial Officer & Company Secretary

 

 

 

finnCap (Nominated Adviser & Broker)

+44 (0)20 7220 0500

Ed Frisby / Scott Mathieson - Corporate Finance

 

Abigail Wayne - Corporate Broking

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

Notes to Editors

Elektron conceives designs and markets innovative engineered products and services for businesses that connect, monitor and control. We have a multi skilled team of engineers, software and product line specialists based in Cambridge focused on the opportunities created by global trends in the following areas:

 

- Demand for ubiquitous power and data: Bulgin

- New waves of "aware" business applications: Checkit

- The effect of ageing on sight: Elektron Eye Technology

- Growth in high precision manufacture: Queensgate

 

Cautionary statement

This financial information has been prepared only for the shareholders of Elektron as a whole and its sole purpose and use is to assist shareholders to exercise their governance rights. Elektron and its Directors and employees are not responsible for any other purpose or use or to any other person in relation to this report.

The report contains indications of likely future developments and other forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and business segments in which the Group operates. Key risks and their mitigation have not changed materially in the period from those disclosed on pages 12 to 14 of the annual financial statements for the year ended 31 January 2017.

These and other factors could adversely affect the Group's results, strategy and prospects. Forward-looking statements involve risks, uncertainties and assumptions. They relate to events and/or depend on circumstances in the future which could cause actual results and outcomes to differ materially from those currently anticipated. No obligation is assumed to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBUBDBCSGBGRB
Date   Source Headline
29th Mar 20187:00 amRNSBulgin announces agreement with Arrow Electronics
6th Mar 20187:00 amRNSFSA successfully completes trials with Checkit
27th Feb 20187:00 amRNSHolding(s) in Company
16th Feb 20187:00 amRNSDisposal of Queensgate Nano
8th Feb 20187:00 amRNSTrading Statement
26th Jan 20183:37 pmRNSHolding(s) in Company
25th Jan 20185:58 pmRNSHolding(s) in Company
25th Jan 20187:00 amRNSAcquisition of IP in EET business
19th Jan 20183:45 pmRNSHolding(s) in Company
2nd Jan 20187:00 amRNSChange of Nominated Adviser and Broker
12th Dec 20177:00 amRNSGrant of Options
6th Dec 20174:02 pmRNSHolding(s) in Company
2nd Nov 20177:00 amRNSTrading Statement
23rd Oct 20174:16 pmRNSDirector/PDMR Shareholding
20th Oct 20177:00 amRNSDisposal of Sheen Instruments
16th Oct 201712:25 pmRNSHolding(s) in Company
27th Sep 20174:20 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSHalf-year Report
19th Sep 20177:00 amRNSContract Win
10th Aug 20177:00 amRNSTrading Update and Notification of Interim Results
31st Jul 20177:00 amRNSDisposal
13th Jul 201710:01 amRNSHolding(s) in Company
6th Jul 20173:00 pmRNSResult of AGM
6th Jul 20177:00 amRNSAGM Statement
16th Jun 201710:40 amRNSHolding(s) in Company
13th Jun 20177:57 amRNSHolding(s) in Company
6th Jun 201711:26 amRNSAnnual Report and Notice of AGM
18th May 20177:00 amRNSFinal Results
2nd May 20177:00 amRNSNotice of Results & AGM
27th Mar 20177:00 amRNSDisposal
8th Feb 20177:00 amRNSTrading Update
19th Jan 20177:00 amRNSDirector/PDMR Shareholding
14th Dec 20164:54 pmRNSHolding(s) in Company
13th Dec 20167:00 amRNSDirector/PDMR Shareholding
8th Dec 20169:00 amRNSReview of Operations
2nd Dec 20167:00 amRNSDisposal
30th Sep 20162:43 pmRNSDisposal of Carnation Designs
22nd Sep 20167:00 amRNSHalf-year Report
30th Aug 20169:52 amRNSHolding(s) in Company
1st Aug 20167:00 amRNSDirector/PDMR Shareholding
28th Jul 20163:56 pmRNSResult of AGM
28th Jul 20167:00 amRNSTrading Update
4th Jul 201610:40 amRNSLapsing of Options
30th Jun 20167:00 amRNSAnnual Report and Notice of AGM
9th Jun 20167:00 amRNSFinal Results
23rd May 20167:00 amRNSDisposal of Agar Scientific
18th May 20169:56 amRNSHolding(s) in Company
13th May 201610:06 amRNSHolding(s) in Company
20th Apr 20162:54 pmRNSDerivative Claim - Update
22nd Feb 20167:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.